GSK2256098

DB16106InvestigationalSmall molecule

GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).

Mechanism: Pharmacologically active on Focal adhesion kinase 1
Curator reviewed
Formula / weight: C₂₀H₂₃ClN₆O₂ · 414.89 g/mol (avg)
Code names: GSK-2256098

Resolves to

Compound

UNIIR7O0O4110GCAS1224887-10-8

Structure

InChIKeyBVAHPPKGOOJSPU-UHFFFAOYSA-NSMILESCONC(=O)C1=CC=CC=C1NC1=CC(NC2=CC(C)=NN2C(C)C)=NC=C1Cl

Targets

Q05397PTK2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with GSK2256098, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account